Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Completed · Phase 1

Conditions studied: Pancreatic Cancer

In brief

To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.

Key facts

Study ID

NCT00243854

Run by

Indiana University

People needed

8

Starts

2005-11-01

Expected to finish

2011-10-01

Last updated by the study team

2014-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• pathologically confirmed adenocarcinoma of the pancreas
• resectable disease
• tumor </= 6cm diameter
• ECOG performance 0-1
• Organ system fxn: granulocytes (>/=1800/uL); plt ct >/=100K; bili</=2mg; liver enzymes <2.5ULN; crt </=1.5;
• Normal CXR
• Negative pregnancy test

You may not qualify if…

• metastatic disease or peritoneal seeding based on cross-sectional imaging
• previous irradiation to the planned field
• prior chemotherapy or immunotherapy
• active infection
• active PUD

Where it is running

• Indiana University Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.